Apellis Pharmactdl 0001 Stock Operating Margin
| 1JK Stock | EUR 31.50 0.51 1.65% |
APELLIS PHARMACTDL 0001 fundamentals help investors to digest information that contributes to APELLIS PHARMACTDL's financial success or failures. It also enables traders to predict the movement of APELLIS Stock. The fundamental analysis module provides a way to measure APELLIS PHARMACTDL's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to APELLIS PHARMACTDL stock.
APELLIS |
APELLIS PHARMACTDL 0001 Company Operating Margin Analysis
APELLIS PHARMACTDL's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current APELLIS PHARMACTDL Operating Margin | (4.60) % |
Most of APELLIS PHARMACTDL's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, APELLIS PHARMACTDL 0001 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, APELLIS PHARMACTDL 0001 has an Operating Margin of -4.5995%. This is 86.89% lower than that of the Healthcare sector and 95.9% lower than that of the Biotechnology industry. The operating margin for all Germany stocks is 16.52% lower than that of the firm.
Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
| All Next | Launch Module |
APELLIS Fundamentals
| Return On Equity | -5.07 | |||
| Return On Asset | -0.46 | |||
| Operating Margin | (4.60) % | |||
| Shares Outstanding | 110.58 M | |||
| Shares Owned By Insiders | 15.32 % | |||
| Shares Owned By Institutions | 89.16 % | |||
| Revenue | 113.05 M | |||
| Gross Profit | (253.92 M) | |||
| EBITDA | (518.43 M) | |||
| Net Income | (460.28 M) | |||
| Cash And Equivalents | 599.01 M | |||
| Cash Per Share | 6.89 X | |||
| Total Debt | 409.63 M | |||
| Debt To Equity | 7.94 % | |||
| Current Ratio | 4.15 X | |||
| Book Value Per Share | 2.78 X | |||
| Cash Flow From Operations | (239.85 M) | |||
| Earnings Per Share | (7.48) X | |||
| Target Price | 67.81 | |||
| Number Of Employees | 767 | |||
| Beta | 1.23 | |||
| Market Capitalization | 5.78 B | |||
| Z Score | 8.4 |
About APELLIS PHARMACTDL Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze APELLIS PHARMACTDL 0001's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of APELLIS PHARMACTDL using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of APELLIS PHARMACTDL 0001 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in APELLIS Stock
APELLIS PHARMACTDL financial ratios help investors to determine whether APELLIS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in APELLIS with respect to the benefits of owning APELLIS PHARMACTDL security.